Orion Oyj (OTCMKTS:ORINY - Get Free Report) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 200 shares, a decline of 66.7% from the April 30th total of 600 shares. Based on an average trading volume of 500 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the company's shares are short sold.
Orion Oyj Price Performance
Shares of ORINY stock remained flat at $33.52 during trading on Friday. 139 shares of the company were exchanged, compared to its average volume of 2,231. The company has a quick ratio of 1.41, a current ratio of 2.42 and a debt-to-equity ratio of 0.25. The firm has a market cap of $9.46 billion, a P/E ratio of 26.60 and a beta of 0.17. The company has a fifty day simple moving average of $30.11 and a 200-day simple moving average of $27.03. Orion Oyj has a 52-week low of $19.97 and a 52-week high of $33.52.
Orion Oyj (OTCMKTS:ORINY - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported $0.23 earnings per share for the quarter. The firm had revenue of $373.03 million during the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. On average, sell-side analysts anticipate that Orion Oyj will post 1.18 EPS for the current fiscal year.
Orion Oyj Increases Dividend
The company also recently declared a dividend, which was paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th were issued a dividend of $0.4478 per share. The ex-dividend date was Monday, April 7th. This is a boost from Orion Oyj's previous dividend of $0.24. Orion Oyj's payout ratio is 24.43%.
Analysts Set New Price Targets
Separately, Nordea Equity Research cut shares of Orion Oyj to a "hold" rating in a report on Tuesday, February 4th.
Get Our Latest Stock Report on ORINY
About Orion Oyj
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
Read More
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
